Construction of Lasso Peptide Fusion Proteins - ACS Chemical

Subscriber access provided by University of Sydney Library

Article

Construction of Lasso Peptide Fusion Proteins Chuhan Zong, Mikhail O. Maksimov, and A. James Link ACS Chem. Biol., Just Accepted Manuscript • DOI: 10.1021/acschembio.5b00745 • Publication Date (Web): 22 Oct 2015 Downloaded from http://pubs.acs.org on October 23, 2015

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

ACS Chemical Biology is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Chemical Biology

207x123mm (100 x 100 DPI)

ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Construction of Lasso Peptide Fusion Proteins Chuhan Zong1, Mikhail O. Maksimov2 and A. James Link2,3*


Page 2 of 35

Page 3 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


TABLE OF CONTENTS



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Construction of Lasso Peptide Fusion Proteins Chuhan Zong1, Mikhail O. Maksimov2 and A. James Link2,3* 1

Department of Chemistry, Princeton University, NJ, 08544

2

Department of Chemical and Biological Engineering, Princeton University, NJ,

08544 3

Department of Molecular Biology, Princeton University, NJ, 08544

Keywords: lasso peptide, protein fusion, phage display

* To whom correspondence should be addressed: A. James Link 207 Hoyt Laboratory Department of Chemical and Biological Engineering Princeton University, NJ, 08544 Phone: 609-258-7191 Email: [email protected]


Page 4 of 35

Page 5 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


ABSTRACT

Lasso

peptides

are

a

family

of

ribosomally-synthesized

and

posttranslationally-modified peptides (RiPPs) typified by an isopeptide-bonded macrocycle between the peptide N-terminus and an aspartate or glutamate sidechain. The C-terminal portion of the peptide threads through the N-terminal macrocycle to give the characteristic lasso fold. Because of the inherent stability, both proteolytic and often thermal, of lasso peptides, we became interested in whether proteins could be fused to the free C-terminus of lasso peptides. Here we demonstrate fusion of two model proteins, the artificial leucine zipper A1 and the superfolder variant of GFP, to the C-terminus of the lasso peptide astexin1. Successful lasso cyclization of the N-terminus of these fusion proteins requires a flexible linker in between the C-terminus of the lasso peptide and the N-terminus of the protein of interest. The ability to fuse lasso peptides to a protein of interest is an important step toward phage and bacterial display systems for the high-throughput screening of lasso peptide libraries for new functions.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 6 of 35

INTRODUCTION

Lasso peptides1,

2

are a growing class of ribosomally-derived natural

products or RiPPs3 in which the N-terminus of the peptide is covalently cyclized with an acidic sidechain.

This forms an isopeptide-bonded “ring” structure

through which the C-terminal portion of the peptide is threaded (Figure 1). Bulky residues in the threaded portion of the peptide prevent unthreading, and these residues are referred to as the steric lock or plug residues.

Lasso peptides

exhibit improved protease resistance4 relative to their linear peptide counterparts. Because of their inherent protease resistance, lasso peptides are attractive starting points for therapeutic peptide development, and our group has previously demonstrated the construction of saturation mutagenesis libraries of the lasso peptide microcin J25 (MccJ25).5

In addition, the integrin-binding tripeptide

epitope RGD has been inserted into MccJ25.6, 7 These studies provide the first glimpses at using lasso peptides as a reprogrammable scaffold. In order to perform high-throughput screens on lasso peptide libraries, it would be desirable to fuse the lasso peptide to an appropriate carrier protein for either phage display or bacterial display. Thus we became interested in whether such lasso peptide fusions could be constructed.

Since lasso peptides do not have a free N-terminus, fusions can only be constructed by adding a peptide or protein to the C-terminus of the peptide. Previous work on MccJ25 showed that addition of 1 or 2 amino acids to the C-


Page 7 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


terminus of this peptide reduced the production of the peptides dramatically, to levels just above the limit of detection.8 Among the structurally characterized lasso peptides,2 MccJ25 is fairly unique because it has a relative long “loop” region with a short “tail” (Figure 1A). Other lasso peptides, such as astexin-1,9, 10 have shorter loop regions and longer tails (Figure 1A). We hypothesized that the longer C-terminal tail region of astexin-1 would be more amenable to fusion with proteins. Here we have shown that astexin-1 fusion proteins can be successfully processed into a lassoed form as long as there is a sufficiently long flexible linker between the C-terminus of the lasso peptide and the fusion protein.

RESULTS AND DISCUSSION

Revisiting the structure of astexin-1. Astexin-1 is a polar, 23 aa lasso peptide, and our group has previously solved the structure of the full-length peptide in DMSO.9 Marahiel and co-workers have also solved a structure of astexin-1 in which the four C-terminal amino acids are truncated, astexin-1 (1-19), in water.10 These two structures differ in the positioning of the steric lock; the structure solved in organic solvent showed Arg-19 serving as the steric lock residue (PDB 2LTI) whereas the structure solved in water (PDB 2M37) implicated Tyr-14 and Phe-15 as the steric lock residues. We suspected that our structure solved in DMSO was partially unthreaded, so here we have solved the full-length astexin-1 structure in H2O/D2O.

COSY, TOCSY, NOESY, and

13

C-HSQC NMR

experiments were carried out on full-length astexin-1 (Figure S1, Figure S2).



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

This new structure (Figure 1A) confirms the steric lock residues as Tyr-14 and Phe-15. When calculated over residues 1-15 (ie, the ring, the loop, and the two steric lock residues), the RMSD between the backbones of the two structures solved in water is 1.09 Å (Figure S3).

Thus in its physiologically-relevant

aqueous form, astexin-1 consists of a 9 aa ring, a 5 aa loop, and a 9 aa tail. This contrasts with MccJ25 where the ring is 8 aa, the loop is 11 aa, and the tail is only 2 aa (Figure 1A).

Direct fusion of protein to the C-terminus of astexin-1. We next turned our attention to whether astexin-1 could accept fusions at its C-terminus. We fused the artificial leucine zipper protein A111, 12 directly to the C-terminus of astexin-1. A1 is small (62 aa, 6.9 kDa), has a simple helical structure, is well-folded, and expresses well in E. coli,12 thus we thought it would be a good starting point as a model protein for fusion to lasso peptides. We generated a plasmid, pCZ1, with the astexin-1 precursor gene (atxA1) fused to the A1 leucine zipper gene. The fusion gene was placed upstream of the maturation enzymes atxB1 and atxC1 (Figure 1B).9 Lasso peptide precursor proteins, such as AtxA1, are comprised of an Nterminal leader peptide13 and the C-terminal core peptide. The leader peptide likely enables docking of the precursor14 within the AtxB1 enzyme while the core peptide is transformed into the final lassoed product. AtxB1-like enzymes are cysteine proteases that cleave the N-terminal leader peptide from AtxA1 and thus generate a new N-terminus that becomes cyclized. AtxC1 and similar enzymes


Page 8 of 35

Page 9 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


are related to asparagine synthetases and use ATP to cyclize the lasso peptide.15, 16 In addition, two control plasmids were constructed: pCZ5 lacks the atxC1 gene and pCZ2 lacks both maturation enzymes. After purifying the protein products of each plasmid, we analyzed them using mass spectrometry. The protein produced from both pCZ1 and pCZ5 had mass of 10349 Da, the mass expected for an astexin-1-A1 fusion with its leader peptide removed, but without dehydration due to cyclization (Figure 2, Figure S4). As expected, the protein product of pCZ2 had a mass matching the unprocessed fusion protein (Figure 2, Figure S4). The lack of any lasso peptide formation in these constructs indicated that perhaps a flexible linker was necessary for the proper function of the cyclization enzyme AtxC1.

However, it is noteworthy that AtxB1 is able to

completely cleave the leader peptide from the precursor both in the presence and absence of AtxC1, indicating that AtxB1 is not sterically hindered from accessing the cleavage site between the leader and core peptide. This is in contrast to an observation in an in vitro study of MccJ25 biosynthesis16 in which McjB, homologous to AtxB1, was unable to cleave the leader peptide from the precursor McjA in the absence of McjC, the homolog of AtxC1.

Introduction of flexible linkers. We hypothesized that the inability of AtxC1 to cyclize C-terminally fused lasso peptides could be due to steric interference of the well-folded A1 structure.

Whereas AtxB1, the lasso peptide precursor

protease, is 209 aa long, the AtxC1 enzyme is much larger, at 572 aa. Thus we generated constructs in which a flexible linker composed of Gly-Ser-Ser-Gly



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(GSSG) repeats was inserted between AtxA1 and the A1 leucine zipper. Two different linker lengths were investigated, (GSSG)2 and (GSSG)5, generating the plasmids pCZ25 and pCZ16, respectively. Gratifyingly, both of these constructs exhibited masses consistent with formation of the lasso peptide at the N-terminus (Figure 3). The conversion of the peptide to the lasso form, however, was not complete. The mass spectrometry data provided a qualitative indication that roughly half of the protein was lassoed. Controls lacking AtxC1 or both of the maturation enzymes behaved as expected (Figure S5, S6).

In order to obtain more quantitative estimates of the extent of lasso formation, we designed another set of constructs in which a thrombin protease cleavage site (LVPRGS, with cleavage between R and G) was placed after the (GSSG)2 or (GSSG)5 linker. This allowed us to remove the lasso peptide from the fusion protein and determine its abundance using the UV detector of an HPLC. The astexin-1-(GSSG)x-thrombin-A1 fusion proteins were analyzed first using SDS-PAGE. Constructs with both maturation enzymes clearly generated two protein products that were resolvable on the gel, presumably the lassoed product and its linear counterpart (Figure 4A) in a roughly 50:50 ratio. Mass spectrometry analysis of the intact protein also showed complete removal of the leader peptide along with roughly 50% conversion to the lasso form (Figure 4B). After thrombin cleavage of the fusion proteins, HPLC analysis with a UV detector at 215 nm revealed three peaks corresponding to the lasso peptide, its linear counterpart, and the cleaved A1 protein (Figure 4C, Figure S7). Integration of


Page 10 of 35

Page 11 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


the peaks for the lasso and linear peptides allowed for quantitative analysis of the extent of lasso peptide formation.

For the astexin-1-(GSSG)2-thrombin-A1

construct, this analysis showed that 49.7 ± 0.3 % of the peptide was lassoed. Results were similar with the astexin-1-(GSSG)5-thrombin-A1 construct with 53.1 ± 0.4 % of the peptide lassoed.

To provide further confirmation that the thrombin-cleaved peptides were indeed lassoed, we purified the astexin-1-(GSSG)2 and astexin-1-(GSSG)5 lasso and linear peptides and analyzed them using MALDI-MS. The masses observed agree with the predicted masses for the lasso and linear forms of the peptide (Figure S8).

The lasso peptides were also subjected to carboxypeptidase

digestion. A mixture of carboxypeptidases B and Y removes amino acids from the C-terminus of the lasso peptide, but are usually unable to cleave beyond the steric lock residues of the lasso peptide, presumably due to steric hindrance.17, 18 In the case of astexin-1, Marahiel and coworkers reported that the four Cterminal

amino

acids

of

full-length

astexin-1

were

removed

upon

carboxypeptidase Y treatment, converting astexin-1 (1-23) into astexin-1 (1-19).10 When we subjected the astexin-1-(GSSG)2 and astexin-1-(GSSG)5 lasso peptides to carboxypeptidase B and Y treatment, we observed astexin-1 (1-20) as a major product in MALDI-MS along with some products resulting from incomplete cleavage (Figure S9). The fact that the carboxypeptidase cocktail cannot cleave beyond this residue is strong confirmation that the astexin-1(GSSG)2 and astexin-1-(GSSG)5 peptides are indeed lassoed.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 12 of 35

Fusing astexin-1 to GFP. Having established that a small, helical leucine zipper protein could be successfully appended to the C-terminus of astexin-1, we next wanted to test the generality of the fusion approach with a larger protein with different tertiary structure. We selected the superfolder variant of GFP19 (sfGFP) for such experiments. sfGFP is much larger than A1, with a mass of 26.8 kDa, and has a β-barrel structure, making it bulkier than the A1 protein. Since the (GSSG)5 linker gave the highest conversion to lasso peptide for the A1 protein, an astexin-1-(GSSG)5-thrombin-sfGFP construct was designed and expressed in E. coli (Figure 5A). The inherent fluorescence of sfGFP is a convenient property to test whether fusion of the lasso peptide has any effect on the fusion protein function.

We

measured

the

fluorescence

intensity

of

three

different

concentrations of purified astexin-1-(GSSG)5-thrombin-sfGFP and compared these measurements to the fluorescence of purified sfGFP alone (Figure S10). We saw no statistically significant difference in fluorescence between the two proteins, indicating that the lasso peptide fusion does not interfere with the folding or chromophore formation of sfGFP.

As was the case with the A1 fusion proteins, ESI-MS analysis of intact astexin-1-(GSSG)5-thrombin-sfGFP fusion protein showed both linear and lassoed forms of astexin-1 (Figure 5B). To quantify the extent of lasso formation, we turned again to thrombin digestion of the fusion protein followed by HPLC quantification (Figure 5C). The percentage of lasso peptide formed was 44.4 ±


Page 13 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


0.6 %, slightly lower than what was observed for the A1 protein. The lasso peptide was also collected and analyzed by MALDI-MS and carboxypeptidase digestion, confirming the identity of this peptide.

Here we have fused two model proteins, the artificial leucine zipper A1 and the superfolder variant of GFP, to the C-terminus of the lasso peptide astexin-1. The successful transformation of the linear lasso peptide precursor into the final threaded form is contingent upon the presence of a flexible linker between the C-terminus of astexin-1 and the N-terminus of the protein. An 8 aa (GSSG)2 linker is sufficient for conversion of ~50% of the astexin-1 precursor into lasso peptide when fused to A1. A longer (GSSG)5 linker also allows for ~50% conversion of astexin-1 when fused to either A1 or sfGFP. Our data indicates that the flexible linker is only required by the AtxC1 enzyme, which forms the isopeptide bond in astexin-1. The other astexin-1 maturation enzyme, AtxB1 is able to cleave the leader peptide from the astexin-1 precursor in both the presence and absence of a flexible linker.

In all of our experiments leader

peptide cleavage, catalyzed by AtxB1, went to completion. This held true even when the gene for AtxC1 was not present in the gene cluster.

This result

challenges the view that B and C enzymes in lasso peptide biosynthesis can function only in the presence of each other.8

In order to quantify the extent of lasso peptide formation, we developed constructs which include a thrombin protease cleavage site after the (GSSG)x



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 14 of 35

linker. In so doing, we have generated lasso peptides with tails as long as 33 amino acids (for the astexin-1-(GSSG)5-thrombin fusions). This construct has a far longer tail than any known, naturally-existing lasso peptide.

The lasso

peptide tail is often susceptible to cleavage both in the native producer17 and in heterologous expression systems such as E. coli.9, 20, 21 Thus our work here has provided a route to such “tail-extended” lasso peptides. The ability to make such constructs opens up the possibility of grafting epitopes of interest into the tail of lasso peptides, which is complementary to the studies cited above6, 7 in which epitopes are grafted directly onto the lasso peptide scaffold. We originally became interested in the problem of lasso peptide fusion proteins because of a desire to develop high-throughput screens for lasso peptide binding to a target of interest. Yeast22 and bacterial23, 24 display systems have been developed for the screening of libraries of other constrained peptide scaffolds such as those based on cystine knots. Adapting these systems to lasso peptides is challenging because the N-terminus of the lasso peptide disappears during its maturation.

This precludes the use of popular phage

display methods, such as fusion to the pIII protein of M13 bacteriophage,25 as well as many bacterial display technologies.26 However, with the ability to fuse lasso peptides to the N-terminus of a display protein, alternative techniques27 including T4,28 P4,29 and lambda30 phage display can be envisioned for lasso peptide display. Another intriguing possibility for lasso peptide display is display on Caulobacter crescentus via its S-layer protein RsaA.31

This protein is

secreted via a C-terminal secretion sequence, and is thus compatible with fusion


Page 15 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


of a lasso peptide to the N-terminus of RsaA or one of its fragments. The fusion of lasso peptides to these phage or bacterial protein scaffolds is expected to expand the toolbox for high-throughput screening of constrained peptide libraries.

METHODS Strains and reagents. PicoMaxx DNA polymerase (Agilent) was used for PCR amplification with primers purchased from IDT.

T4 ligase and restriction

enzymes EcoRI, BglII, and KpnI for cloning were purchased from New England Biolabs. The XL-1 Blue E. coli strain was used for all recombinant DNA steps, while BL-21 ∆slyD was used for protein expression.

Plasmid construction. Table S1 includes a list of all plasmids used in this paper.

All new plasmids were derived from pQE-80 which includes a T5

promoter, a copy of lacIq, and an ampicillin resistance marker. The primers used to generate each construct are listed in Table S1, and the sequences of all primers appear in Table S2. The pCA14 plasmid includes the atxB1C1 operon encoding the astexin-1 maturation enzymes AtxB1 and AtxC1. This operon was amplified using PCR from the pMM32 plasmid9 and digested with BglII and HindIII. This product was ligated into similarly digested pQE80. To generate fusions between astexin-1 and the A1 leucine zipper,11 overlap PCR was employed. The atxA1 gene encoding the astexin-1 precursor was amplified from pMM32 with a 5’ EcoRI site. The gene encoding the A1 leucine zipper includes a C-terminal 6x-His tag and was amplified from pQE9-A111 with a 3’ BglII site.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 16 of 35

These two fragments were joined by overlap PCR, digested with EcoRI and BglII, and ligated into similarly digested pCA14, resulting in the plasmid pCZ1. The pCZ5 plasmid is a control for pCZ1, and it consists of the gene encoding the astexin-1-A1 fusion and just the AtxB1 maturation enzyme.

A PCR product

spanning the astexin-1-A1 fusion gene and AtxB1 was generated with a 3’ end KpnI site. This product was digested with EcoRI and KpnI and ligated into pQE80 to generate pCZ5. The pCZ2 plasmid is an additional control for pCZ1 and lacks both the AtxB1 and AtxC1 maturation enzymes. It was constructed in the same way as pCZ5.

The

pCZ16/pCZ20/pCZ21

plasmid

series

is

analogous

to

pCZ1/pCZ5/pCZ2 described above except that a flexible glycine-serine linker, (GSSG)5 was inserted between astexin-1 and the A1 leucine zipper. The gene encoding astexin-1-(GSSG)5-A1 was assembled by overlap PCR. The (GSSG)5 fragment was amplified from pJP4715 while the astexin-1 and A1 gene fragments were amplified from pCZ1. Once assembled, the PCR product was digested as above for pCZ1 and ligated into pCA14 to generate pCZ16. The pCZ20 and pCZ21 plasmids were generated in an analogous fashion to pCZ5 and pCZ2. The pCZ43 plasmid is similar to pCZ16 except it also includes a thrombin cleavage site between the glycine-serine linker and A1. pCZ43 was assembled in the same way as pCZ16, except that primers encoding the thrombin cleavage site were used. Control plasmids pCZ44 and pCZ45 were made in an analogous fashion to pCZ20 and pCZ21.

A set of plasmids with shorter glycine-serine


Page 17 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


linkers, (GSSG)2, were also constructed, both without (pCZ25, pCZ26, pCZ27) and with (pCZ29, pCZ40, pCZ39) thrombin cleavage sites. These plasmids were derived from the constructs with the (GSSG)5 linker.

Finally, plasmids with genes encoding for astexin-1-(GSSG)5-superfolder GFP (pCZ22) and astexin-1-(GSSG)5-thrombin-superfolder GFP (pCZ46) were constructed in the same way as pCZ16 and pCZ43, respectively.

The

superfolder GFP fragment was amplified from pDA38, which is a pQE60 derivative with the C-terminally 6x His-tagged superfolder GFP gene19 inserted in the multiple cloning site. All plasmid sequences were verified by Genewiz.

Purification of astexin-1. Expression and purification of astexin-1 were carried out in similar fashion as the purification of astexin-321 with some minor changes. Briefly, BL21 E. coli cells harboring the plasmid pMM32 (contains the atxA1B1C1 operon) were grown in M9 minimal medium and induced at an OD600 of 0.2 to 0.3 to produce astexin-1.

The cells were lysed in methanol, and the insoluble

fraction was removed by centrifugation. The methanol-soluble fraction, which contains astexin-1, was dried in a rotary evaporator, reconstituted in minimal water, and cleaned up using solid-phase extraction (Strata C8, 6 mL). Crude astexin-1 was eluted from the column using methanol which was subsequently removed using a rotary evaporator.

The peptide was purified using HPLC

(Zorbax 300SB-C18 Semi-Prep HPLC Column, 9.4 by 250 mm, Agilent Technologies) by applying the following solvent gradient at a flow-rate of 4.0



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

mL/min: 10% acetonitrile (ACN) in water for 1 min, ramp up to 50% ACN over 19 min, ramp up to 90% ACN over 5 min, 90% ACN for 5 min, ramp down to 10% ACN in 2 min. HPLC fractions containing astexin-1 were pooled and lyophilized (Labconco Freezone 4.5/-105 °C) resulting in a white powder.

NMR Spectroscopy of Astexin-1. The HPLC-purified astexin-1 (1.3 mg) was dissolved in 95:5 H2O/D2O (180 µL). COSY, TOCSY, NOESY (100 ms mixing time), and

13

C-HSQC spectra were acquired on a Bruker Avance III 800 MHz

spectrometer. All residues were assigned, and an initial structure was calculated using CYANA.32

The structure was energy-minimized in explicit water using

GROMACS33 and the amber94 force field using a procedure adapted from Spronk et al.34 Refinement of structures in explicit water has been shown to improve overall quality and provide a more accurate representation of the conformational flexibility within the structure.35-37 After introducing the isopeptide bond, each structure was energy-minimized in vacuo for 100 steps using the limited-memory BFGS algorithm. The resulting structure was placed under a periodic boundary condition such that no atom was closer than 10 Å from the simulation box and solvated in water using the tip3p model. A short energy minimization was applied to soak the water molecules into the structure, followed by 0.5 ps of MD at 300 K. The isothermal-isobaric ensemble was chosen. A total of 25 ps of MD were performed for each structure, while cooling the system from 300 K to 50 K in four steps. During the simulation, the force constant


Page 18 of 35

Page 19 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


associated with NMR derived distance restraints was decreased from 20,000 to 8,000 kJ mol-1 nm-2. The top 20 structures are presented in the PDB file.

Fusion protein expression. Plasmids were introduced into BL-21 ∆slyD for protein expression.

Cells harboring plasmids encoding either astexin-1-A1

fusions or astexin-1-sfGFP fusions were grown in LB medium (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) with 100 mg/L ampicillin (Affymetrix) for plasmid maintenance. In a typical experiment, an overnight culture was diluted to an OD600 of 0.02, and the culture was grown at 37 °C until reaching an OD600 of 0.5.

At this time, the culture was shifted to room temperature (~21 °C),

induced with 1 mM isopropyl-β-D-1-thiogalactopyranoside (Gold Biotechnology), and allowed to express protein for 16 h.

Cells then were harvested by

centrifugation at 8,000 x g for 10 min at 4 °C, and cell pellets were frozen at -80 °C until needed for purification.

Fusion protein purification. Following protein expression, astexin-1-A1 fusion proteins and astexin-1-sfGFP fusion proteins were purified under native conditions. Cell pellets were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8). The cells were incubated for 30 min on ice with the addition of 0.25 mg/ml lysozyme (Sigma Aldrich), and lysed by sonication. Following lysis, cells were centrifuged at 10,000 x g for 10 min at 4 °C, and the supernatants containing fusion proteins were purified on Ni-NTA



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 20 of 35

resin according to the manufacturer’s recommendation (Qiagen). Purified proteins were analyzed by SDS-PAGE.

ESI-MS analysis of intact fusion protein. Electrospray ionization mass spectrometric (ESI-MS) analysis of fusion proteins was performed on a Bruker Daltonics MicroTOF-Q II mass spectrometer. Purified fusion proteins were first purified by HPLC using the same gradient and conditions described in the “Purification of astexin-1” section. Fusion proteins were collected based on their retention times on HPLC and subsequently lyophilized.

Lyophilized samples

were reconstituted in MS buffer (50% acetonitrile, 0.1% formic acid in H2O) and injected into the mass spectrometer. The observed average molecular weight of each fusion protein sample was obtained by deconvolution of the acquired intensity vs. m/z data using the Maximum Entropy algorithm (Spectrum Square Associates). Theoretical average molecular weights for the fusion proteins were calculated using mMass.

Thrombin digestion of fusion proteins and HPLC analysis. Prior to thrombin digestion, proteins were purified via HPLC as described in the previous paragraph. The peak corresponding to the intact protein was collected and the protein solution was lyophilized. This dried protein was reconstituted in thrombin cleavage buffer 1 (1x PBS, pH 7.3) for the A1 fusion proteins or thrombin cleavage buffer 2 (50 mM Tris, pH 8.0) for the sfGFP fusion proteins. Thrombin digestion assays were performed with 1.5-2 U thrombin (GE Healthcare) to


Page 21 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


cleave 450-750 µg of astexin-1-A1 fusion protein in 150-200 µL thrombin cleavage buffer 1 for 16 h at room temperature (~21 °C). For each astexin-1sfGFP fusion protein sample, thrombin digestion assays were performed with 3 U thrombin (GE Healthcare) to cleave 900-1300 µg protein in 300 µL thrombin cleavage buffer 2 (50mM Tris, pH 8) for 16 h at room temperature (~21 °C). Following thrombin digestion, digested fusion proteins were analyzed on HPLC using the same solvent gradient described above in the ESI-MS section. The typical injection volume of astexin-1-A1 fusion protein digests was 75-100 µL while the injection volume of astexin-1-sfGFP fusions was 290 µL. To quantify the percentage of lasso peptide, the area under the peaks of the lasso peptide and the linear were determined using the HPLC software and the percentage of lasso peptide was calculated as (area under lasso peak)/(area under lasso peak + area under linear peak). The percentage of lasso formation was calculated as the average of 3 or 4 biological replicates, and the error reported is the standard deviation of those measurements. The cleaved peptides (both lasso and linear) were also collected based on their retention time, dried under reduced pressure (DyNAVap, LabNet), and analyzed by MALDI mass spectrometry as well as carboxypeptidase digestion.

MALDI-MS analysis of thrombin-cleaved peptides. Acquisition of mass spectra in the m/z 500-6000 range was performed using an ABSciex 4800 Plus MALDI TOF/TOF Analyzer (ABSciex). The instrument was set to positive ion mode. Dried samples were resuspended in water, diluted with a 2.5 mg/ml



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 22 of 35

solution of α-Cyano-4-hydroxycinnamic acid matrix and spotted onto an Applied Biosystem(ABI) 384 Opti-TOF 123 mm x 81 mm SS plate.

Carboxypeptidase digestion assays. Dried thrombin-cleaved lasso peptides and linear peptides were digested with 0.5 U carboxypeptidase B (Sigma-Aldrich) and 0.5 U carboxypeptidase Y (Affymetrix) in carboxypeptidase digestion buffer (50 mM sodium acetate, pH 6.0) for 3 h at room temperature. Digested samples were further analyzed by MALDI-MS as described above.

sfGFP Fluorescence intensity measurement. For a typical fluorescence intensity measurement, 100µl of purified sfGFP or astexin-1-(GSSG)5-Thb-sfGFP at 2.5 µM, 5 µM and 10 µM, in elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8) was added to a Costar 96-well black plate (Fisher Scientific) and equilibrated at 24 °C for 5 min. determined

using

the

BCA

assay

Protein concentrations were

according

to

the

manufacturer’s

recommendations (Pierce). Maximum emission at 510 nm was measured upon excitation with 485 nm light. The fluorescence level was measured in a BioTek Synergy 4 plate reader. Three technical replicates were performed for each concentration.

Accession numbers The coordinates for the astexin-1 structure have been deposited to the PDB (accession number 2N68) and the BMRB (accession number 25754).


Page 23 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Supporting Information Supporting Information is available free of charge on ACS Publications website at DOI: http://pubs.acs.org. Supporting information includes 2-D NMR spectra, supplementary tables and supplementary figures.

ACKNOWLEDGEMENTS We thank T. Muir for the use of the ESI-MS instrument. This work was supported by NIH grant GM107036. AJL is a Sloan Research Fellow in Chemistry.

REFERENCES (1) Maksimov, M. O., Pan, S. J., and Link, A. J. (2012) Lasso peptides: structure, function, biosynthesis, and engineering, Nat. Prod. Rep. 29, 996-1006. (2) Hegemann, J. D., Zimmermann, M., Xie, X., and Marahiel, M. A. (2015) Lasso Peptides: An Intriguing Class of Bacterial Natural Products, Acc. Chem. Res. 48, 1909-1919. (3) Arnison, P. G., Bibb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., Camarero, J. A., Campopiano, D. J., Challis, G. L., Clardy, J., Cotter, P. D., Craik, D. J., Dawson, M., Dittmann, E., Donadio, S., Dorrestein, P. C., Entian, K.D., Fischbach, M. A., Garavelli, J. S., Goransson, U., Gruber, C. W., Haft, D. H., Hemscheidt, T. K., Hertweck, C., Hill, C., Horswill, A. R., Jaspars, M., Kelly, W. L., Klinman, J. P., Kuipers, O. P., Link, A. J., Liu, W., Marahiel, M. A., Mitchell, D. A., Moll, G. N., Moore, B. S., Muller, R., Nair, S. K., Nes, I. F., Norris, G. E.,



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Olivera, B. M., Onaka, H., Patchett, M. L., Piel, J., Reaney, M. J. T., Rebuffat, S., Ross, R. P., Sahl, H.-G., Schmidt, E. W., Selsted, M. E., Severinov, K., Shen, B., Sivonen, K., Smith, L., Stein, T., Sussmuth, R. D., Tagg, J. R., Tang, G.-L., Truman, A. W., Vederas, J. C., Walsh, C. T., Walton, J. D., Wenzel, S. C., Willey, J. M., and van der Donk, W. A. (2013) Ribosomally synthesized and posttranslationally modified peptide natural products: overview and recommendations for a universal nomenclature, Nat. Prod. Rep. 30, 108-160. (4) Pomares, M. F., Salomon, R. A., Pavlova, O., Severinov, K., Farias, R., and Vincent, P. A. (2009) Potential Applicability of Chymotrypsin-Susceptible Microcin J25 Derivatives to Food Preservation, Appl. Environ. Microb. 75, 5734-5738. (5) Pan, S. J., and Link, A. J. (2011) Sequence Diversity in the Lasso Peptide Framework: Discovery of Functional Microcin J25 Variants with Multiple Amino Acid Substitutions, J. Am. Chem. Soc. 133, 5016-5023. (6) Knappe, T. A., Manzenrieder, F., Mas-Moruno, C., Linne, U., Sasse, F., Kessler, H., Xie, X. L., and Marahiel, M. A. (2011) Introducing Lasso Peptides as Molecular Scaffolds for Drug Design: Engineering of an Integrin Antagonist, Angew. Chem.- Int. Edit. 50, 8714-8717. (7) Hegemann, J. D., De Simone, M., Zimmermann, M., Knappe, T. A., Xie, X., Di Leva, F. S., Marinelli, L., Novellino, E., Zahler, S., Kessler, H., and Marahiel, M. A. (2014) Rational Improvement of the Affinity and Selectivity of Integrin Binding of Grafted Lasso Peptides, J. Med. Chem. 57, 5829-5834. (8) Ducasse, R., Yan, K. P., Goulard, C., Blond, A., Li, Y. Y., Lescop, E., Guittet, E., Rebuffat, S., and Zirah, S. (2012) Sequence Determinants Governing the


Page 24 of 35

Page 25 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Topology and Biological Activity of a Lasso Peptide, Microcin J25, Chembiochem 13, 371-380. (9) Maksimov, M. O., Pelczer, I., and Link, A. J. (2012) Precursor-centric genome-mining approach for lasso peptide discovery, P. Natl. Acad. Sci. USA 109, 15223-15228. (10) Zimmermann, M., Hegemann, Julian D., Xie, X., and Marahiel, Mohamed A. (2013) The Astexin-1 Lasso Peptides: Biosynthesis, Stability, and Structural Studies, Chem. Biol. 20, 558-569. (11) Petka, W. A., Harden, J. L., McGrath, K. P., Wirtz, D., and Tirrell, D. A. (1998) Reversible hydrogels from self-assembling artificial proteins, Science 281, 389-392. (12) Tang, Y., and Tirrell, D. A. (2001) Biosynthesis of a highly stable coiled-coil protein containing hexafluoroleucine in an engineered bacterial host, J. Am. Chem. Soc. 123, 11089-11090. (13) Cheung, W. L., Pan, S. J., and Link, A. J. (2010) Much of the Microcin J25 Leader Peptide is Dispensable, J. Am. Chem. Soc. 132, 2514-2515. (14) Burkhart, B. J., Hudson, G. A., Dunbar, K. L., and Mitchell, D. A. (2015) A prevalent peptide-binding domain that guides ribosomal natural product biosynthesis, Nat. Chem. Biol. 11, 564-570. (15) Pan, S. J., Rajniak, J., Cheung, W. L., and Link, A. J. (2012) Construction of a Single Polypeptide that Matures and Exports the Lasso Peptide Microcin J25, Chembiochem 13, 367-370.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(16) Yan, K. P., Li, Y. Y., Zirah, S., Goulard, C., Knappe, T. A., Marahiel, M. A., and Rebuffat, S. (2012) Dissecting the Maturation Steps of the Lasso Peptide Microcin J25 in vitro, Chembiochem 13, 1046-1052. (17) Iwatsuki, M., Tomoda, H., Uchida, R., Gouda, H., Hirono, S., and Omura, S. (2006) Lariatins, antimycobacterial peptides produced by Rhodococcus sp K01B0171, have a lasso structure, J. Am. Chem. Soc. 128, 7486-7491. (18) Hegemann, J. D., Zimmermann, M., Xie, X. L., and Marahiel, M. A. (2013) Caulosegnins I-III: A Highly Diverse Group of Lasso Peptides Derived from a Single Biosynthetic Gene Cluster, J. Am. Chem. Soc. 135, 210-222. (19) Pedelacq, J. D., Cabantous, S., Tran, T., Terwilliger, T. C., and Waldo, G. S. (2006) Engineering and characterization of a superfolder green fluorescent protein, Nat. Biotechnol. 24, 79-88. (20) Hegemann, J. D., Zimmermann, M., Zhu, S. Z., Klug, D., and Marahiel, M. A. (2013) Lasso Peptides From Proteobacteria: Genome Mining Employing Heterologous Expression and Mass Spectrometry, Biopolymers 100, 527-542. (21) Maksimov, M. O., and Link, A. J. (2013) Discovery and Characterization of an Isopeptidase That Linearizes Lasso Peptides, J. Am. Chem. Soc. 135, 1203812047. (22) Silverman, A. P., Levin, A. M., Lahti, J. L., and Cochran, J. R. (2009) Engineered Cystine-Knot Peptides that Bind alpha(v)beta(3) Integrin with Antibody-Like Affinities, J. Mol. Biol. 385, 1064-1075.


Page 26 of 35

Page 27 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(23) Getz, J. A., Cheneval, O., Craik, D. J., and Daugherty, P. S. (2013) Design of a Cyclotide Antagonist of Neuropilin-1 and-2 That Potently Inhibits Endothelial Cell Migration, ACS Chem. Biol. 8, 1147-1154. (24) Getz, J. A., Rice, J. J., and Daugherty, P. S. (2011) Protease-Resistant Peptide Ligands from a Knottin Scaffold Library, ACS Chem. Biol. 6, 837-844 (25) Kehoe, J. W., and Kay, B. K. (2005) Filamentous phage display in the new millennium, Chem. Rev. 105, 4056-4072. (26) Chen, W., and Georgiou, G. (2002) Cell-surface display of heterologous proteins: From high-throughput screening to environmental applications, Biotechnol. Bioeng. 79, 496-503. (27) Sergeeva, A., Kolonin, M. G., Molldrem, J. J., Pasqualini, R., and Arap, W. (2006) Display technologies: Application for the discovery of drug and gene delivery agents, Adv. Drug Deliver. Rev. 58, 1622-1654. (28) Jiang, J., Abu-Shilbayeh, L., and Rao, V. B. (1997) Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface, Infect. Immun. 65, 4770-4777. (29) Lindqvist, B. H., and Naderi, S. (1995) Peptide presentation by bacteriophage P4, FEMS Microbiol. Rev. 17, 33-39. (30) Vaccaro, P., Pavoni, E., Monteriu, G., Andrea, P., Felici, F., and Minenkova, O. (2006) Efficient display of scFv antibodies on bacteriophage lambda, Journal Immunol. Methods 310, 149-158. (31) Nomellini, J. F., Duncan, G., Dorocicz, I. R., and Smit, J. (2007) S-layermediated display of the immunoglobulin G-binding domain of streptococcal



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

protein G on the surface of Caulobacter crescentus: Development of an immunoactive reagent, Appl. Environ. Microb. 73, 3245-3253. (32) Guntert, P., Mumenthaler, C., and Wuthrich, K. (1997) Torsion angle dynamics for NMR structure calculation with the new program DYANA, J. Mol. Biol. 273, 283-298. (33) Pronk, S., Pall, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., Hess, B., and Lindahl, E. (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit, Bioinformatics 29, 845-854. (34) Spronk, C., Linge, J. P., Hilbers, C. W., and Vuister, G. W. (2002) Improving the quality of protein structures derived by NMR spectroscopy, J. Biomol. NMR 22, 281-289. (35) Spronk, C., Nabuurs, S. B., Krieger, E., Vriend, G., and Vuister, G. W. (2004) Validation of protein structures derived by NMR spectroscopy, Prog. Nucl. Magn. Reson. Spectrosc. 45, 315-337. (36) Linge, J. P., Williams, M. A., Spronk, C., Bonvin, A., and Nilges, M. (2003) Refinement of protein structures in explicit solvent, Proteins 50, 496-506. (37) Spronk, C., Nabuurs, S. B., Bonvin, A., Krieger, E., Vuister, G. W., and Vriend, G. (2003) The precision of NMR structure ensembles revisited, J. Biomol. NMR 25, 225-234.


Page 28 of 35

Page 29 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


FIGURE CAPTIONS Figure 1: Lasso peptide structure and gene cluster architecture. A) Comparison of the sequence and structure of two lasso peptides, microcin J25 (PDB 1Q71) and astexin-1 (this work) with the ring (salmon), loop (blue), and tail (green) sections indicated. The steric lock residues are shown in pink. Whereas microcin J25 has a long loop and a short tail, astexin-1 has a short loop and a long tail. B) Gene clusters for astexin-1 production (top) and astexin-1-fusion production (bottom). The fusion protein gene is added to the 3’ end of the astexin-1 precursor gene atxA1. Gene sizes not drawn to scale. Figure 2: Maturation of astexin-1 precursor fusion proteins. A) Schematic of lasso peptide fusion protein maturation. The precursor to astexin-1 consists of a leader peptide (purple) and the core peptide (orange) that is converted into the lasso. Linkers (green), when present, are placed between the C-terminus of the core peptide and the fusion protein (red). The cysteine protease AtxB1 cleaves the leader peptide while the asparagine synthetase homolog AtxC1 generates the isopeptide bond that defines the lasso fold. B) Constructs tested in this study and average masses (expected) of the various processed forms. A1: A1 artificial leucine zipper, sfGFP: superfolder GFP, (GSSG)x: Gly-Ser-Ser-Gly repeat, Thb: thrombin cleavage site. Figure 3: Mass spectrometry of astexin-1-A1 fusion proteins with flexible linkers. A) Deconvoluted electrospray mass spectrum of the astexin-1-(GSSG)2A1 construct showing a roughly 50:50 split between the lassoed and linear core peptide forms of the protein. B) As in A, but for the astexin-1-A1-(GGSG)5-A1 construct. a.u.: arbitrary units. Figure 4: Quantification of the extent of lasso formation in astexin-1 fusion proteins. Left panels correspond to astexin-1-(GSSG)2-thrombin-A1 protein, right panels correspond to astexin-1-(GSSG)5-thrombin-A1 protein. A) SDSPAGE gel of purified astexin-1 fusion proteins, lane 1: intact astexin-1 gene cluster, lane 2: gene cluster lacking atxC1, lane 3: gene cluster lacking atxB1 and atxC1. When both maturation enzymes are present, a mixture of lassoed and linear core peptide forms of the protein is produced (lane 1). If only the AtxB1 enzyme is present, the leader peptide is removed completely, but no lasso formation occurs (lane 2). If neither AtxB1 nor AtxC1 is present, the leader



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

peptide is not cleaved. B) Electrospray mass spectra of the mixture of lassoed and linear protein corresponding to the protein in lane 1 of panel A. C) HPLC analysis of thrombin-digested astexin-1 fusion proteins. The area under the curve was computed to determine the ratio of lassoed to linear protein. Figure 5: Fusion of astexin-1 to superfolder GFP (sfGFP). A) Gene cluster for astexin-1 sfGFP fusion production and model of the astexin-1-(GSSG)5thrombin-sfGFP fusion protein. The (GSSG)5-thrombin-sfGFP portion of the protein was modeled in I-TASSER and then connected to the NMR structure of astexin-1. This illustration is intended to provide a sense of size of the linker and the lasso peptide relative to GFP. B) Mass spectrum of the mixture of lassoed and linear protein produced by the gene cluster in A. C) HPLC analysis of thrombin-digested astexin-1-(GSSG)5-thrombin-sfGFP protein.


Page 30 of 35

Page 31 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


FIGURES Figure 1



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 2


Page 32 of 35

Page 33 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 3



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 4


Page 34 of 35

Page 35 of 35

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 5


Construction of Lasso Peptide Fusion Proteins - ACS Chemical

Recommend Documents